At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available
In Brief
A Phase 1 clinical trial evaluating IMC-A12 for Advanced Solid Tumors. Completed, enrolled 24 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine if IMC-A12 is safe for participants, and also to determine the best dose of IMC-A12 to give to participants.
Study Details
Timeline
Interventions
Cohort 1 3 milligrams/kilogram (mg/kg), I.V. once a week, for 4 weeks, followed by a 2-week observation period.
Cohort 2 6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.
Cohort 3 10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.
Cohort 4 15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.
Cohort 5 21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.
Cohort 6 27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.